Subscribe to RSS
DOI: 10.1055/s-0042-104520
Diagnostik des Vorhofflimmerns und Beurteilung des Schlaganfallrisikos – Wie viel Vorhofflimmern ist zu viel Vorhofflimmern?
Diagnosis of atrial fibrillation and determination of stroke risk – How much of atrial fibrillation is too much?Publication History
Publication Date:
03 May 2016 (online)
Vorhofflimmern ist definiert als eine Folge supraventrikulärer Extrasystolen von mehr als 30 Sekunden Dauer. Diese Definition ist arbiträr. Sie entspricht nicht dem tatsächlichen thromboembolischen Risiko, das durch Vorhofflimmern beeinflusst wird. Das Schlaganfallsrisiko bei Vorhofflimmern wird zum einen durch die Dauer, aber wesentlicher noch durch klinische Variablen bestimmt. Eine frühzeitige effektive Antikoagulation oder thromboembolische Präventionstherapie, wie sie auch durch den Vorhofohroccluder möglich ist, ist sinnvoll [24] [32] [34].
Atrial fibrillation is defined as a sequence of supraventricular extrasystoles of more than 30 seconds. This definition is arbitrarily. It does not correspond to the actual thromboembolic risk that is affected by atrial fibrillation. The risk of stroke in atrial fibrillation is essential determined by the duration of atrial fibrillation, but even more important by clinical variables. Early effective anticoagulation or thromboembolic prevention therapy (i.e. LAA occlusion) is useful.
-
Literatur
- 1 Bhatt A, Majid A, Razak A et al. Predictors of Occult Paroxysmal Atrial Fibrillation in Cryptogenic Strokes Detected by Long-Term Noninvasive Cardiac Monitoring Stroke. Res Treat Art. ID 172074 2011;
- 2 Boriani G, Glotzer TV, Santini M et al. Device-detected atrial fibrillation and risk forstroke: an analysis of >10.000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J 2014; 35: 508-516
- 3 Botto GL, Padeletti L, Santini M et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 2009; 20: 241-248
- 4 Brambatti M, Connolly SJ, Gold MR et al. Temporal relationship between subclinical atrial fibrillation and embolic events. Circulation 2014; 129: 2094-2099
- 5 Breitenstein A, Steffel J. Die Virchow-Trias in der Thrombogenese beim Vorhofflimmern. Schweiz Med Forum 2014; 14: 673-675
- 6 Bunch AT, May HT, Bair TL et al. Atrial fibrillation ablation patients have long-term stroke rates similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm 2013; 10: 1272-1277
- 7 Calkins H, Kuck KH, Cappato R et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2012; 9: 632-696
- 8 Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747
- 9 Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429
- 10 Daoud EG, Glotzer TV, Wyse DG et al. Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS. Heart Rhythm 2011; 8: 1416-1423
- 11 Feinberg WM, Blackshear JL, Laupacis A et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155: 469-473
- 12 Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation Cohort Study. Eur Heart J 2012; 33: 1500-1510
- 13 Furberg CD, Psaty BM, Manolio TA et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-241
- 14 Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870
- 15 Gaillard N, Deltour S, Vilotijevic B et al. Detection of paroxysmal atrial fibrillation with transtelephonic EKG in TIA or stroke patients. Neurology 2010; 74: 1666-1670
- 16 Gladstone DJ, Spring M, Dorian P et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014; 26: 2467-2477
- 17 Glotzer TV, Daoud EG, Wyse DG et al. The Relationship Between Daily Atrial Tachyarrhythmia Burden From Implantable Device Diagnostics and Stroke Risk: The TRENDS Study. Circ Arr Electrophysiol 2009; 2: 474-480
- 18 Gregory YH, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272
- 19 Gustafsson C, Blombäck M, Britton M et al. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990; 21: 47-51
- 20 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867
- 21 Hart RG, Pearce LA, Rothbart RM et al. Stroke With Intermittent Atrial Fibrillation: Incidence and Predictors During Aspirin Therapy. J Am Coll Cardiol 2000; 35: 183-187
- 22 January CT, Wann LS, Alpert JS et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 2014; 130
- 23 Holmes DR, Reddy VY, Turi ZG et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009; 374: 534-542
- 24 Khan M, Miller DJ. Detection of Paroxysmal Atrial Fibrillation in Stroke/Tia Patients. Stroke Res Treat Art. ID 840265 2013;
- 25 Lamas G. How Much Atrial Fibrillation Is Too Much Atrial Fibrillation?. N Engl J Med 2: 178-180
- 26 Lip GY, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272
- 27 Lip GY, Frison L, Halperin JL, Lane DA. Identifying Patients at High Risk for Stroke Despite Anticoagulation A Comparison of Contemporary Stroke Risk Stratification Schemes in an Anticoagulated Atrial Fibrillation Cohort. Stroke 2010; 41: 2731-2738
- 28 Miller DJ, Khan MA, Schultz LR et al. Outpatient cardiac telemetry detects a high rate of atrial fibrillation in cryptogenic stroke. J Neurol Sci 2013; 324: 57-61
- 29 Piccini JP, Stevens SR, Chang Y et al. Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation. Circulation 2013; 127: 224-232
- 30 Pisters R, Lane DA, Nieuwlaat R et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-100
- 31 Sanna T, Diener HC, Passmann RS et al. Cryptogenic Stroke and Underlying Atrial Fibrillation. N Engl J Med 2014; 26: 2478-2486
- 32 Steinberg BA, Hellkamp AS, Lokhnygina Y et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J 2015; 36: 288-296
- 33 Tayal AH, Tian M, Kelly KM et al. Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke. Neurology 2008; 71: 1696-1701
- 34 Themistoclakis S, Corrado A, Marchlinski FE et al. The Risk of Thromboembolism and Need for Oral Anticoagulation After Successful Atrial Fibrillation Ablation. J Am Coll Cardiol 2010; 55: 735-743
- 35 Tziakas DN, Chalikias GK, Papanas N et al. Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation. Europace 2007; 9: 589-596